8 results
Equianalgesic Opioid Dosing 

#Pharmacology #Pain #Opioid #Opiate #Conversion #Equianalgesic #Table
Equianalgesic Opioid Dosing ... #Pharmacology ... #Pain #Opioid # ... Opiate #Conversion ... Equianalgesic #Table
Transdermal Fentanyl require unique dosing conversions. For Adult and pediatric patients taking opiouds or doses not
require unique dosing ... conversions. ... Then using Table ... #Pharmacology #Pain ... Opiate #Opioid #Conversion
Pain Assessment and Management Initiative (PAMI) - Opioid Prescribing and Equianalgesic Chart - Agents and Dosing

#Management
Pain Assessment ... #Pharmacology # ... Equianalgesics #Conversion ... #Doses #Dosing ... #Table #PAMI
Anti-infective stewardship, including tips for using anti-infectives wisely, criteria for stepdown from IV to PO dosage
including tips for using ... anti-infectives ... dosage forms and conversion ... #pharmacology #antibiotics ... #medications #table
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
GLP-1 Agonists ... Daily GLP-1 Agonists ... site pain. --- ... #Pharmacology #Dosing ... Diabetes #DM2 #Endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
GLP-1 Receptor Agonists ... - Pharmacology ... Ozempic), or daily tablet ... #Pharmacology # ... DM2 #diabetes #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
Dosing: 3 mg ... oral route by using ... drug to remain stable ... semaglutide #Diabetes #Pharmacology ... #Endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... GLP-I receptor agonist ... Toxicities: • Joint pains ... DPP4 #Inhibitors #Pharmacology ... DM2 #diabetes #endocrinology